Myriad Genetics, Inc. updated earnings guidance for the year 2025. For the year, the company expects revenue to be $807 million - $823 million compared to previous guidance of $840 million - $860 million. Lowered 2025 revenue range mid-point by $35 million reflecting an updated outlook for pharmacogenomics business and hereditary cancer testing in Women's Health business.